Novel Experiential Technologies Assisting Individual Learning (NExT AI) Hubs (P20 Clinical Trial Optional)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 3 Jun 2026
- Closes
- 2 Oct 2026, 23:59 UTC
- Value
- USD 1,600,000
- Reference
- RFA-HD-27-006
- Location
- United States
- Sector
- Healthcare & Pharma
Details
This Notice of Funding Opportunity (NOFO) invites exploratory grant applications, hereafter referred to as the Novel Experiential Technologies Assisting Individual learning Hubs or NExT AI Hubs (formerly Learning Disabilities Innovation Hubs), to address the impact of Artificial Intelligence (AI) technologies on developmental outcomes in children diagnosed with or at risk for developing a specific learning disability (SLD) impacting reading, writing, and mathematics. NExT AI Hubs include a single Research Project and a Leadership Core that support the goals and aims of the Hub. This NOFO seeks to serve as a catalyst to 1) speed the maturation of nascent/novel, high-impact, high-risk research that advances understanding of the role AI technology plays in supporting, improving, or limiting the learning, cognitive, and socio-emotional needs of children at risk for or diagnosed with SLDs, 2) build an evidence base for the SLD community to inform policy or practice, and 3) provide project-embedded, career-enhancing research and professional development opportunities to support the next generation of transdisciplinary SLD scientists. This initiative provides opportunities to support planning and building a body of research and corresponding intellectual infrastructure to enable NExT AI investigators to compete for large research and program project opportunities in the future.This NOFO aims to integrate research topics that are of relevance to various research programs at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and align with the NICHD Strategic Plan. The NOFO intends to build cross-programmatic, transdisciplinary and cross-cutting scientific research, and critically nurture the development of early career investigators capable of conducting this research. Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Estimated total programme funding: USD 1600000
Expected number of awards: 3
CFDA number(s): 93.865
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 408 notices from National Institutes of Health, going back to May 2023 — 390 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 398 open Healthcare & Pharma tenders in United States. This one closes in 8 days.
More from this buyer
- Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)· closes 10 Nov
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)· closes 10 Nov
- Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed)· closes 12 Jun
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)· closes 10 Nov
- Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)· closes 9 Oct
Similar Healthcare & Pharma tenders
- Advancing bio-printing of living cells for regenerative medicine· closes 22 Sept
- Development of cell-free protein synthesis platforms for discovery and/or production of biologicals· closes 13 Apr
- Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential· closes 13 Apr
- Development of innovative antimicrobials against pathogens resistant to antimicrobials· closes 13 Apr
- Development of monoclonal antibodies to prevent and treat infections from Flaviviruses· closes 13 Apr
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Provision of Private Hospital Capacity to support Urgent and Emergency CareHealth Service Executive (HSE) · Ireland
- Panel for Counselling and Psychotherapy ServicesUniversity College Dublin ( UCD ) · Ireland
- HSE 28439 - Restricted Procedure to procure a HSE Enterprise Integration Platform as a Service ( EiPaaS)Health Service Executive (HSE) · Ireland
- Provision of Occupational Health ServicesUisce Éireann · Ireland
- Supply of Accessibility Ramps, Wheelchair lifts, Parts and Servicing, Maintenance and TrainingBus Eireann/Irish Bus · Ireland
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →